CPL Brochure - June 2025

CLINICAL PROTEOMICS LABORATORY

Founded by the Center for Applied Proteomics and Molecular Medicine in 2008 CAP/ CLIA Accredited

ACCELERATING DISCOVERY TO CLINIC Accreditation by the College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) ensures the lab adheres to rigorous clinical and regulatory standards. This allows for faster, more reliable translation of research into real-world solutions. Full-service research support is available for academic collaborators, biotech startups, pharmaceutical companies, and government agencies.

ABOUT THE CLINICAL PROTEOMICS LABORATORY The Clinical Proteomics Laboratory is a CAP- and CLIA-accredited facility specializing in advanced proteomics and biomarker research. W ith a mission to accelerate biomedical innovation, the lab supports the development of early diagnostic tools and personalized treatments for cancer, infectious diseases, and neurodegenerative conditions. W hile housed within the Center for Applied Proteomics and Molecular Medicine (CAPMM), the lab operates with a distinct focus on translational science, bridging research and clinical application through validated, regulatory-compliant methods.

ACCELERATING DISCOVERY TO CLINIC Accreditation by the College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) ensures the lab adheres to rigorous clinical and regulatory standards. This allows for faster, more reliable translation of research into real-world solutions. Full-service research support is available for academic collaborators, biotech startups, pharmaceutical companies, and government agencies.

ABOUT THE CLINICAL PROTEOMICS LABORATORY The Clinical Proteomics Laboratory is a CAP- and CLIA-accredited facility specializing in advanced proteomics and biomarker research. W ith a mission to accelerate biomedical innovation, the lab supports the development of early diagnostic tools and personalized treatments for cancer, infectious diseases, and neurodegenerative conditions. W hile housed within the Center for Applied Proteomics and Molecular Medicine (CAPMM), the lab operates with a distinct focus on translational science, bridging research and clinical application through validated, regulatory-compliant methods.

OUR TECHNOLOGIES

OUR CAP-COMPLIANT SERVICES

The Clinical Proteomics Laboratory provides advanced analytical and translational research services, helping partners move biomedical discoveries from bench to bedside. Leveraging state-of-the-art tools and expert support, we offer end-to-end solutions for researchers, clinicians, and industry collaborators aiming to advance precision medicine.

Our team uses patented technologies developed by CAPMM scientists, including:

Advanced biomarker discovery using mass spectrometry and protein microarrays

Biomarker verification and validation

Development of precision diagnostics

Infectious disease testing, immunohistochemistry, and proteomic assays Reverse Phase Protein Microarray A powerful multiplex immunoassay that quantifies hundreds of proteins and post-translational modifications from small cell samples

Nanot rap® Technology (Licensed by Ceres Nanosciences, Inc.)

Laser Capt ure Microdissect ion

Enables isolation of pure cell populations A tool that captures under microscopic and protects rare visualization for disease biomarkers directly from blood, high-precision studies urine, and saliva for enhanced analysis

Support for clinical trial implementation

Experimental design, data, and documentation preparation for FDA submission

OUR TECHNOLOGIES

OUR CAP-COMPLIANT SERVICES

The Clinical Proteomics Laboratory provides advanced analytical and translational research services, helping partners move biomedical discoveries from bench to bedside. Leveraging state-of-the-art tools and expert support, we offer end-to-end solutions for researchers, clinicians, and industry collaborators aiming to advance precision medicine.

Our team uses patented technologies developed by CAPMM scientists, including:

Advanced biomarker discovery using mass spectrometry and protein microarrays

Biomarker verification and validation

Development of precision diagnostics

Infectious disease testing, immunohistochemistry, and proteomic assays Reverse Phase Protein Microarray A powerful multiplex immunoassay that quantifies hundreds of proteins and post-translational modifications from small cell samples

Nanot rap® Technology (Licensed by Ceres Nanosciences, Inc.)

Laser Capt ure Microdissect ion

Enables isolation of pure cell populations A tool that captures under microscopic and protects rare visualization for disease biomarkers directly from blood, high-precision studies urine, and saliva for enhanced analysis

Support for clinical trial implementation

Experimental design, data, and documentation preparation for FDA submission

SCIENCE IN CAPMM THAT CHANGES LIVES Advancing Lyme Disease Detect ion A novel protein-based urine test was developed at George Mason University for faster, more accurate diagnosis of Lyme disease. In collaboration with Johns Hopkins and Inova, the team is leveraging the Clinical Proteomics Laboratory to identify early biomarkers to support timely treatment and expand detection to other tickborne illnesses.

Advancing Precision Medicine for Cancer Pat ient s George Mason scientists used cutting-edge technologies including reverse phase protein array and laser capture microdissection to identify protein activation signatures that reveal how patients respond to treatment. In collaboration with leading oncology partners through the I-SPY 2 Trial, the DoD APOLLO Cancer Moonshot Program, Inova Schar Cancer Institute, and the Side-Out Foundation, this work helps drive more personalized and effective cancer therapies.

Dr. Lance Liot t a

Dr. Emanuel "Chip" Pet ricoin

RESEARCH LEADERSHIP AT CAPMM Dr. Lance Liot t a is Co-Director and Co-Founder of the Center for Applied Proteomics and Molecular Medicine at George Mason University. Previously, he served as Chief of the Laboratory of Pathology at the National Cancer Institute and Deputy Director of the NIH. He is known for co-inventing Laser Capture Microdissection and developing technologies that have shaped cancer diagnostics and molecular research.

Dr. Emanuel F. Pet ricoin is Co-Director and Co-Founder of the Center for Applied Proteomics and Molecular Medicine and a University Professor at George Mason University. Prior to Mason, he served as a Senior Investigator at the FDA, where he co-led the FDA-NCI Clinical Proteomics Program. His work bridges proteomic innovation and clinical application, with a focus on biomarker discovery and therapeutic guidance.

SCIENCE IN CAPMM THAT CHANGES LIVES Advancing Lyme Disease Detect ion A novel protein-based urine test was developed at George Mason University for faster, more accurate diagnosis of Lyme disease. In collaboration with Johns Hopkins and Inova, the team is leveraging the Clinical Proteomics Laboratory to identify early biomarkers to support timely treatment and expand detection to other tickborne illnesses.

Advancing Precision Medicine for Cancer Pat ient s George Mason scientists used cutting-edge technologies including reverse phase protein array and laser capture microdissection to identify protein activation signatures that reveal how patients respond to treatment. In collaboration with leading oncology partners through the I-SPY 2 Trial, the DoD APOLLO Cancer Moonshot Program, Inova Schar Cancer Institute, and the Side-Out Foundation, this work helps drive more personalized and effective cancer therapies.

Dr. Lance Liot t a

Dr. Emanuel "Chip" Pet ricoin

RESEARCH LEADERSHIP AT CAPMM Dr. Lance Liot t a is Co-Director and Co-Founder of the Center for Applied Proteomics and Molecular Medicine at George Mason University. Previously, he served as Chief of the Laboratory of Pathology at the National Cancer Institute and Deputy Director of the NIH. He is known for co-inventing Laser Capture Microdissection and developing technologies that have shaped cancer diagnostics and molecular research.

Dr. Emanuel F. Pet ricoin is Co-Director and Co-Founder of the Center for Applied Proteomics and Molecular Medicine and a University Professor at George Mason University. Prior to Mason, he served as a Senior Investigator at the FDA, where he co-led the FDA-NCI Clinical Proteomics Program. His work bridges proteomic innovation and clinical application, with a focus on biomarker discovery and therapeutic guidance.

W HY WORK W ITH US The Clinical Proteomics Laboratory brings the scientific rigor and strategic insight needed to accelerate meaningful clinical solutions. The multidisciplinary team brings deep expertise in proteomics, translational research, and diagnostics development with a track record of patenting cutting-edge technologies and delivering high-impact peer-reviewed publications.

YOUR NEXT STEP STARTS HERE As Director of the Clinical Proteomics Laboratory, I look forward to exploring how we can help translate your discoveries to the bedside. Our team brings decades of experience in CAP/ CLIA-accredited environments and translational research. We?re committed to collaborating with you to design tailored studies that meet regulatory standards and deliver high-quality results.

Virginia Espina vespina@gmu.edu, 703-993-8062